Opinion|Videos|August 19, 2024
Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations
The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Looking ahead, what is the most critical priority to meaningfully enhance outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations?
Advertisement
Related to this article
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
FDA Approves First Heart Valve to Keep Pace With Children's Growth
5